CHRS Q4 2020 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$110M-10.8% YoY

Gross Profit

$99M89.4% margin

Operating Income

$16M14.9% margin

Net Income

$10M8.8% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

-2.8%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$32M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$842M

Total Liabilities

$561M

Stockholders' Equity

$281M

Cash & Equivalents

$541M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$110M	$124M	-10.8%
Gross Profit	$99M	$116M	-14.9%
Operating Income	$16M	$45M	-63.5%
Net Income	$10M	$39M	-75.3%